Tuesday, February 26, 2019 10:35:29 AM
Tue February 26, 2019 7:52 AM|GlobeNewswire|About: BSGM
Santa Monica, CA, Feb. 26, 2019 (GLOBE NEWSWIRE) -- ?BioSig Technologies (BITKF), Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company appointed a Senior R&D Engineer and is working on further senior biomedical engineering hires to support BioSig’s growing manufacturing processes and advanced R&D activities.
Mr. Fui Veavea brings to the Company over 29 years of manufacturing and engineering experience in a range of medical device sectors, including implantable class III devices, diabetes-monitoring and respiratory diagnostic systems. During his career Mr. Veavea acquired a wealth of knowledge in semiconductor, computer programming and validation and installation of sensors. He successfully led a number of product transfer and manufacturing processes and is highly experienced in regulatory matters, including quality design assurance and post-market surveillance. Mr. Veavea is a holder of various certifications, honors and awards, such as RAND Worldwide Certificate of Achievement to Pro-Engineer (2000).
“One of our internal goals for 2019 is the expansion of our engineering talents to augment the success and expansion we are seeing in other areas. Fui’s experience in a wide range of product development and quality control arenas is something that attracted BioSig. As we build on the primary goals with delivering high quality human data, we seek to increase internal talent to support our manufacturing processes during this important chapter in our Company’s development. We are confident that Fui will make a valuable addition to our team and look forward to his contributions,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies.
On February 20, 2019 the Company announced that it successfully conducted first patient cases using PURE EP(tm) System, its FDA approved proprietary signal acquisition and processing technology. The first commercial use of the System was completed at the Texas Cardiac Arrhythmia Institute (“TCAI”) in Austin, TX under the leadership of Andrea Natale, M.D., F.A.C.C., F.H.R.S., F.E.S.C., Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center. Early results of the studies suggested improved cardiac signal detection and fidelity.
The Company released its Shareholder Letter earlier in February 2019, where it stated its intentions to present the results from the First-in-Human studies and the early feedback from the use of the PURE EP(tm) System to a larger community of physicians during the Heart Rhythm Society event in May 2019.
About BioSig Technologies
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace (www.biosig.com). Led by a proven management team and a veteran Board of Directors, BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market.
The Company’s first product, PURE EP™ System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision-making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
12424 Wilshire Blvd, Ste 745
Los Angeles, CA 90025
ndrapeau@biosigtech.com
310-620-9320
Recent BSGM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 08:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 08:00:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:07:09 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/01/2024 04:15:16 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/31/2024 09:05:20 PM
- BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation • GlobeNewswire Inc. • 07/31/2024 01:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 01:27:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 01:25:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 01:24:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 01:22:50 AM
- BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024 • GlobeNewswire Inc. • 07/25/2024 05:57:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 05:05:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/05/2024 08:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/05/2024 08:00:19 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/05/2024 08:00:17 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/05/2024 08:00:15 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/27/2024 07:17:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/26/2024 08:40:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 04:40:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 01:45:12 PM
- BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer • GlobeNewswire Inc. • 06/10/2024 01:45:00 PM
- BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 05/30/2024 08:05:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM